Dual receptor antagonistic antigen-binding proteins and uses thereof
This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
1. An isolated antigen-binding protein comprising SEQ ID NO: 25 and a second polypeptide comprising SEQ ID NO: 26 wherein the antigen binding protein specifically binds to SEQ ID NO: 2 and SEQ ID NO: 18.
2. An isolated nucleic acid encoding the antigen-binding protein of claim 1 .
3. An expression vector comprising the nucleic acid of claim 2 .
4. A host cell comprising the vector of claim 3 .
5. The host cell of claim 4 wherein the cell is a eukaryotic or prokaryotic cell.
6. The host cell of claim 5 wherein the eukaryotic cell is a mammalian cell.
7. A method of producing an antigen-binding protein, comprising culturing the host cell of claim 4 under suitable conditions such that the nucleic acid is expressed to produce the antibody.
8. The method of claim 7 , further comprising recovering the antibody from a culture of the host cell.
9. A composition comprising the antigen-binding protein of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
10. A method of increasing lean muscle mass or increasing the ratio of lean muscle mass to fat mass in a subject in need of such treatment comprising administering an effective amount the antigen-binding protein or a pharmaceutical composition containing the antigen binding protein of claim 1 to a subject in need of such treatment.
11. A method of treating or preventing a muscle wasting disease in a subject suffering from such a disorder comprising administering an effective amount of a therapeutic composition containing the antigen-binding polypeptide of claim 1 to the subject.